Verified Nov 2026
Other
·

Paramus, New Jersey
·
Since 1999
NS Pharma, Inc. is a U.S. pharmaceutical subsidiary of Japan-based Nippon Shinyaku, founded in 1999 and headquartered in Paramus, New Jersey. With 100–200 employees and estimated revenue between $100–250 million, the company develops therapies for rare and incurable diseases across hematology, urology, gynecology, neurology, and inflammatory conditions. It brought Viltepso to market for Duchenne Muscular Dystrophy and pursues exon-skipping therapies and JAK1 inhibition platforms.
NS Pharma, Inc. at a glance
Revenue
$100-250M
Est. band
Employees
100-200
Founded
1999
Headquarters
Paramus, New Jersey
Industries
Automotive
Electric Vehicles
Medical
Industrial Equipment
Overview
NS Pharma, Inc. is a U.S. pharmaceutical subsidiary of Japan-based Nippon Shinyaku, founded in 1999 and headquartered in Paramus, New Jersey. With 100–200 employees and estimated revenue between $100–250 million, the company develops therapies for rare and incurable diseases across hematology, urology, gynecology, neurology, and inflammatory conditions. It brought Viltepso to market for Duchenne Muscular Dystrophy and pursues exon-skipping therapies and JAK1 inhibition platforms.
At a glance
Attribute | Detail |
|---|---|
Founded | 1999 |
Headquarters | Paramus, New Jersey |
Employees | 100-200 |
Revenue | $100-250M (estimated) |
What NS Pharma, Inc. makes
The company specializes in orphan drug development, with recent focus on exon-skipping therapies for muscular dystrophy and JAK1 inhibition approaches for inflammatory diseases.
Latest developments
2026-07-30 — NS Pharma Parent Company, Nippon Shinyaku, Exercises Option Rights for Commercialization of AB2 Bio’s Tadekinig alfa in the U.S. - NSPharma (nspharma.com)
2026-06-25 — Nippon Shinyaku and Elixirgen Therapeutics Enter Option Agreement for Development and Commercialization of EXG-7001 for Duchenne Muscular Dystrophy - NSPharma (nspharma.com)
2026-06-23 — NS Pharma Parent Company, Nippon Shinyaku, Announces Sponsored Research Agreement with Boston Children’s Hospital - NSPharma (nspharma.com)
2026-04-16 — We’re proud to share our parent company, Nippon Shinyaku, recently announced its collaboration with xFOREST Therapeutics. | NS Pharma, Inc. (linkedin.com)
2025-09-19 — FDA Grants Orphan Drug Designation to NS-051/NCNP-04 for the Treatment of Duchenne Muscular Dystrophy - NSPharma (nspharma.com)
2025-07-01 — NS Pharma Announces Strategic Alliance with Boston Children's Hospital to Develop New Therapies for Rare Diseases - NSPharma (nspharma.com)
Facilities
NS Pharma, Inc. is headquartered in Paramus, New Jersey. Public sources also reference these locations:
Kyoto, Japan — nspharma.com
Company details
NS Pharma operates as a subsidiary of Nippon Shinyaku and collaborates with academic institutions and biotechnology partners, including a sponsored research agreement with Boston Children's Hospital announced in June 2026. NS Pharma, Inc. was founded in 1999, has an estimated 100-200 employees, and is headquartered in Paramus, New Jersey.
Frequently asked questions
What does NS Pharma, Inc. do?
NS Pharma, Inc. is a U.S. pharmaceutical subsidiary of Japan-based Nippon Shinyaku, founded in 1999 and headquartered in Paramus, New Jersey. With 100–200 employees and estimated revenue between $100–250 million, the company develops therapies for rare and incurable diseases across hematology, urology, gynecology, neurology, and inflammatory conditions. It brought Viltepso to market for Duchenne Muscular Dystrophy and pursues exon-skipping therapies and JAK1 inhibition platforms.
Where is NS Pharma, Inc. headquartered?
NS Pharma, Inc. is headquartered in Paramus, New Jersey (140 East Ridgewood Avenue, Paramus, New Jersey, 07652).
When was NS Pharma, Inc. founded?
NS Pharma, Inc. was founded in 1999.
How big is NS Pharma, Inc.?
NS Pharma, Inc. has an estimated 100-200 employees, with revenue in the $100-250M range (estimated).
Related suppliers
Explore other suppliers in the LightSource directory:
Last verified Nov 2026. Is this your company? Request a correction.
Location & contact
Evaluating suppliers like these?
This profile is part of a public-data sample of the full LightSource directory. Book a demo to see the full LightSource marketplace and supplier discovery platform — 1M+ credible suppliers, with AI-run sourcing events.
